Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold

Key Points

• Wall Street Zen upgraded Avalo Therapeutics from “sell” to “hold,” while broader analyst sentiment remains more positive, with a consensus “Moderate Buy” rating and an average price target of $45.10.
• AVTX opened at $19.59, compared with a 52-week range of $8.41 to $24.27, and has a market capitalization of approximately $1.05 billion. The company reported a quarterly loss of $0.83 per share, missing the $0.58 loss estimate.
• Institutional investors own approximately 87.06% of the stock, while insider ownership stands at 4.46%; an insider recently sold 1,450 shares under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Sunday.

Several other research analysts have also recently weighed in on AVTX. Piper Sandler restated an "overweight" rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Guggenheim set a $48.00 price objective on shares of Avalo Therapeutics and gave the company a "buy" rating in a research note on Friday, August 7th. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They issued an "outperform" rating and a $38.00 price objective for the company. HC Wainwright dropped their target price on shares of Avalo Therapeutics from $35.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Finally, BTIG Research restated a "buy" rating and issued a $58.00 target price on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Avalo Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $45.10.

Avalo Therapeutics Stock Performance

AVTX opened at $19.59 on Friday. The stock has a fifty day moving average of $17.82 and a 200-day moving average of $16.43. Avalo Therapeutics has a fifty-two week low of $8.41 and a fifty-two week high of $24.27. The company has a market capitalization of $1.05 billion, a P/E ratio of -4.48 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, equities research analysts predict that Avalo Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insider Activity at Avalo Therapeutics

In related news, insider Mittie Doyle sold 1,450 shares of the business's stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the transaction, the insider directly owned 51,776 shares of the company's stock, valued at approximately $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is owned by insiders.

Institutional Trading of Avalo Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics in the second quarter worth about $56,000. Dimensional Fund Advisors LP bought a new position in shares of Avalo Therapeutics during the 3rd quarter valued at approximately $143,000. AlphaCentric Advisors LLC bought a new position in shares of Avalo Therapeutics during the 1st quarter valued at approximately $174,000. Jump Financial LLC purchased a new stake in shares of Avalo Therapeutics during the 4th quarter worth approximately $238,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Avalo Therapeutics during the 4th quarter worth approximately $274,000. Hedge funds and other institutional investors own 87.06% of the company's stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source